Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Arry 142886
2. Arry-142886
3. Arry142886
4. Azd 6244
5. Azd-6244
6. Azd6244
1. 606143-52-6
2. Azd6244
3. Arry-142886
4. Azd 6244
5. 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
6. Azd-6244
7. Selumetinib (azd6244)
8. Arry 142886
9. Arry-886
10. Azd6244 (selumetinib)
11. 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide
12. Koselugo
13. 5-(4-bromo-2-chlorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide
14. Chembl1614701
15. Chebi:90227
16. 6uh91i579u
17. Nsc741078
18. Ncgc00189073-01
19. Ncgc00189073-02
20. 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
21. Dsstox_cid_28870
22. Dsstox_rid_83139
23. Dsstox_gsid_48944
24. 1h-benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-
25. 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
26. Azd 6244;5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzo[d]imidazole-5-carboxamide
27. Cas-606143-52-6
28. Arry142886
29. Selumetinib [usan:inn]
30. Selumetinibum
31. Unii-6uh91i579u
32. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-
33. 3ew
34. 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
35. Selumetinib [mi]
36. Selumetinib [inn]
37. Selumetinib (usan/inn)
38. Selumetinib [usan]
39. Azd6244 - Selumetinib
40. Selumetinib [who-dd]
41. Schembl155456
42. Gtpl5665
43. Selumetinib, Arry-142886
44. Dtxsid3048944
45. Ex-a020
46. Bcpp000367
47. Hms3244g03
48. Hms3244g04
49. Hms3244h03
50. Hms3265k01
51. Hms3265k02
52. Hms3265l01
53. Hms3265l02
54. Hms3654o03
55. Nsc 741o78
56. Bcp01739
57. Tox21_113362
58. Bdbm50355497
59. Mfcd11977472
60. Nsc800882
61. S1008
62. Zinc31773258
63. Akos015904255
64. Tox21_113362_1
65. Bcp9000354
66. Ccg-264774
67. Cs-0059
68. Db11689
69. Ex-8621
70. Nsc-741078
71. Nsc-800882
72. Sb14707
73. Ncgc00189073-07
74. 6-(4-bromo-2-chloro-anilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide
75. Ac-25059
76. Am808016
77. Azd6244,selumetinib, Arry-142886
78. Hy-50706
79. Selumetinib (arry142886/azd6244)
80. Azd6244 (selumetinib,arry-142886)
81. Ft-0674552
82. Sw202561-3
83. D09666
84. 143a526
85. Q-101405
86. Q7448840
87. Brd-k57080016-001-01-9
88. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2- Hydroxyethoxy)-1-methyl-
89. 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-1,3-benzodiazole-6-carboxamide
90. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy -ethoxy)-amide
91. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy-ethoxy)-amide
92. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid(2-hydroxy-ethoxy)-amide
93. 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxyethoxy)-amide
94. 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid(2-hydroxyethoxy)-amide
95. 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy-ethoxy)-amide
| Molecular Weight | 457.7 g/mol |
|---|---|
| Molecular Formula | C17H15BrClFN4O3 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 456.00001 g/mol |
| Monoisotopic Mass | 456.00001 g/mol |
| Topological Polar Surface Area | 88.4 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 523 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients 2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
FDA Label
Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above
Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor. By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer. Indeed, a study investigating the effects of selumetinib in children with NF-1 found that treatment with the anti-neoplastic resulted in reduced tumor size. Decreases in tumor-associated pain and improvements in overall function were also subjectively reported. Selumetinib has minimal off-target activity, contributing to its impressive safety profile.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EE - Mitogen-activated protein kinase (mek) inhibitors
L01EE04 - Selumetinib
Absorption
Based on several studies investigating selumetinib at various doses in both pediatric and adult populations, the Tmax generally ranges between 1- 1.5 hours. In healthy adults, the mean absolute oral bioavailability was reported to be 62%. Selumetinib should be administered on an empty stomach since food significantly decreases serum concentrations of the drug.
Route of Elimination
Approximately 59% of selumetinib is eliminated in the feces, while 33% is eliminated in the urine.
Volume of Distribution
The mean apparent volume of distribution of selumetinib at steady state in pediatric patients ranged from 78 L to 171 L. A study in healthy adult males found a mean apparent volume of distribution of 146 L. Another study observing the pharmacokinetic effects of various selumetinib doses and regimens in select Japanese patients found that the apparent volume of distribution values at steady-state ranged from 73.2 - 148.1 L.
Clearance
The clearance of selumetinib in pediatric patients is 8.8 L/hr. A study in healthy adult males found a clearance value of 15.7 L/hr. Another study observing the pharmacokinetic effects of various selumetinib doses and regimens in select Japanese patients found clearance values that ranged from 9.2 - 15.9 L/hr.
Selumetinib is heavily metabolized in the liver and the proposed metabolic pathway is as follows: Hydrolysis of selumetinibs amide functional group produces M15 (AZ13326637), which contains a carboxylic acid. Elimination of the ethanediol moiety from the parent compound results in the formation of the primary amide M14 (AZ12791138) metabolite. Amide hydrolysis transforms M14 into M15, glucuronidation and further oxidation of M14 leads to M2, M6 and M1, and N-demethylation of M14 produces M12. The amide glucuronide (M2) is thought to be the major circulating metabolite. Demethylation of selumetinib produces the pharmacologically active M8 (AZ12442942), and further oxidation of M8 leads to M11. Glucuronidation of M8 produces M3 or M5, and elimination of the ethanediol moiety from M8 results in a primary amide, producing M12. Although the N-demethylated metabolite (M8) accounts for <10% of the circulating metabolites, it is responsible for approximately 21-35% of any observed pharmacological activity. Ribose conjugation transforms M12 into M9, while oxidation of M12 leads to M10 and M13 metabolites. Glucuronidation of M10 produces M1. Direct glucuronidation of selumetinib produces M4 or M7, which can both eventually transform into M3 and M5 metabolites.
Selumetinib is characterized by a short half-life. The elimination half-life associated with a dose of 25 mg/m2 in pediatric patients is 6.2 hours. In a study observing the pharmacokinetic effects of various selumetinib regimens in select Japanese patients, the half-life ranged from 9.2- 10.6 hours. In other studies where selumetinib 75 mg is administered twice daily, the half-life is reported to be approximately 13 hours.
The Ras-Raf-MEK-ERK signaling cascade is known to be activated in several types of cancer, and regulates the transcription of proteins involved in apoptosis. In addition, studies have shown that mutations of the Raf component of the pathway can contribute to chemotherapy drug resistance. Ras as well as several kinases and phosphatases are responsible for regulating the Raf-MEK-ERK pathway. Often in cancers, Ras (a G-protein coupled receptor) is deregulated, allowing downstream signalling to proceed unchecked. Through several complex steps, Raf phosphorylates and activates MEK, which then phosphorylates and activates ERK. ERK is then able to exert its effects on several downstream targets. As such, therapies inhibiting upstream components of this pathway have become attractive targets for cancer treatment. Selumetinib exerts its effects by selectively inhibiting MEK1 and MEK2 which can effectively blunt the pleiotropic effects of the Ras-Raf-MEK-ERK cascade. By inhibiting this oncogenic pathway, selumetinib reduces cell proliferation, and promotes pro-apoptotic signal transduction.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41492
Submission : 2025-03-31
Status : Active
Type : II
NDC Package Code : 52076-6278
Start Marketing Date : 2023-07-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43833
Submission : 2026-03-29
Status : Active
Type : II
NDC Package Code : 54893-0523
Start Marketing Date : 2026-03-28
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43936
Submission : 2026-03-31
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 54864-874
Start Marketing Date : 2020-04-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6278
Start Marketing Date : 2023-07-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54864-874
Start Marketing Date : 2020-04-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0523
Start Marketing Date : 2026-03-28
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers cost-effective APIs with speed, supported by a skilled team. As the first Southeast Asian company to receive FDA approv...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 10mg
Packaging :
Approval Date : 29/07/2022
Application Number : 67410
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 25mg
Packaging :
Approval Date : 29/07/2022
Application Number : 67410
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 2020-04-10
Application Number : 213756
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 25MG BASE
Packaging :
Approval Date : 2020-04-10
Application Number : 213756
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : GRANULE;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2025-09-10
Application Number : 219943
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : GRANULE;ORAL
Dosage Strength : EQ 7.5MG BASE
Packaging :
Approval Date : 2025-09-10
Application Number : 219943
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : CAPSULE; ORAL
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number : 219943
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : KOSELUGO
Dosage Form : CAPSULE; ORAL
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number : 219943
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Kiss logo
Dosage Form : Capsule
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Kiss logo
Dosage Form : Capsule
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : KOSELUGO
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 10MG BASE
Approval Date : 2020-04-10
Application Number : 213756
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : KOSELUGO
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 25MG BASE
Approval Date : 2020-04-10
Application Number : 213756
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : KOSELUGO
Dosage Form : GRANULE;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2025-09-10
Application Number : 219943
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : KOSELUGO
Dosage Form : GRANULE;ORAL
Dosage Strength : EQ 7.5MG BASE
Approval Date : 2025-09-10
Application Number : 219943
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : KOSELUGO
Dosage Form : CAPSULE; ORAL
Dosage Strength : 10MG
Approval Date :
Application Number : 219943
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : KOSELUGO
Dosage Form : CAPSULE; ORAL
Dosage Strength : 25MG
Approval Date :
Application Number : 219943
RX/OTC/DISCN :
RLD :
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 10mg
Packaging :
Approval Date : 29/07/2022
Application Number : 67410
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 25mg
Packaging :
Approval Date : 29/07/2022
Application Number : 67410
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Kiss logo
Dosage Form : Capsule
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Kiss logo
Dosage Form : Capsule
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Koselugo
Dosage Form : Capsule
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 25MG
Packaging :
Approval Date : 27-07-2021
Application Number : 1211552002
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Koselugo
Dosage Form : Hard Capsule
Dosage Strength : 10MG
Packaging :
Approval Date : 27-07-2021
Application Number : 1211552001
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Koselugo
Dosage Form : Hard Capsules
Dosage Strength : 10mg
Packaging :
Approval Date : 19-06-2021
Application Number : 28106418020
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Kiss Logo
Dosage Form : Capsule
Dosage Strength : 5mg
Packaging :
Approval Date : 09-01-2026
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Kiss Logo
Dosage Form : Capsule
Dosage Strength : 7.5mg
Packaging :
Approval Date : 09-01-2026
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Reply
02 Jun 2025
Reply
07 May 2024
Reply
24 Jul 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2026-03-13
US Patent Number : 8178693
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219943
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-03-13

Patent Expiration Date : 2029-03-26
US Patent Number : 11813246
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213756
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-26

Patent Expiration Date : 2026-12-12
US Patent Number : 9562017
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 219943
Patent Use Code : U-4357
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-12-12

Patent Expiration Date : 2026-03-13
US Patent Number : 8178693
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 213756
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-03-13

Patent Expiration Date : 2026-12-12
US Patent Number : 9562017
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 219943
Patent Use Code : U-4357
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-12-12

Patent Expiration Date : 2026-12-12
US Patent Number : 9156795
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219943
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-12-12

Patent Expiration Date : 2028-03-13
US Patent Number : 7425637
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 219943
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-03-13

Patent Expiration Date : 2029-03-26
US Patent Number : 12364684
Drug Substance Claim :
Drug Product Claim :
Application Number : 213756
Patent Use Code : U-4357
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-26

Patent Expiration Date : 2029-03-26
US Patent Number : 12220403
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213756
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-26

Patent Expiration Date : 2029-03-26
US Patent Number : 12318367
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213756
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-26

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NPP
Exclusivity Expiration Date : 2028-11-19
Application Number : 213756
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NPP
Exclusivity Expiration Date : 2028-09-10
Application Number : 213756
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-288
Exclusivity Expiration Date : 2027-04-10
Application Number : 213756
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NPP
Exclusivity Expiration Date : 2028-09-10
Application Number : 213756
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NPP
Exclusivity Expiration Date : 2028-11-19
Application Number : 213756
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-288
Exclusivity Expiration Date : 2027-04-10
Application Number : 213756
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NP
Exclusivity Expiration Date : 2028-09-10
Application Number : 219943
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NPP
Exclusivity Expiration Date : 2028-11-19
Application Number : 219943
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE*
Exclusivity Expiration Date : 2027-04-10
Application Number : 219943
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NP
Exclusivity Expiration Date : 2028-09-10
Application Number : 219943
Product Number : 2
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2023-03-13
Date Granted : 2009-01-06
Brand Name : KOSELUGO
Patent Number : 2478374
Filing Date : 2003-03-13
Strength per Unit : 10 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2023-03-13
Date Granted : 2009-01-06

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2026-12-12
Date Granted : 2013-08-13
Brand Name : KOSELUGO
Patent Number : 2634149
Filing Date : 2006-12-12
Strength per Unit : 10 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2026-12-12
Date Granted : 2013-08-13

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-03-26
Date Granted : 2016-02-09
Brand Name : KOSELUGO
Patent Number : 2718653
Filing Date : 2009-03-26
Strength per Unit : 10 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-03-26
Date Granted : 2016-02-09

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2023-03-13
Date Granted : 2009-01-06
Brand Name : KOSELUGO
Patent Number : 2478374
Filing Date : 2003-03-13
Strength per Unit : 25 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2023-03-13
Date Granted : 2009-01-06

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2026-12-12
Date Granted : 2013-08-13
Brand Name : KOSELUGO
Patent Number : 2634149
Filing Date : 2006-12-12
Strength per Unit : 25 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2026-12-12
Date Granted : 2013-08-13

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-03-26
Date Granted : 2016-02-09
Brand Name : KOSELUGO
Patent Number : 2718653
Filing Date : 2009-03-26
Strength per Unit : 25 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-03-26
Date Granted : 2016-02-09

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
96
PharmaCompass offers a list of Selumetinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Selumetinib manufacturer or Selumetinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Selumetinib manufacturer or Selumetinib supplier.
A Selumetinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selumetinib, including repackagers and relabelers. The FDA regulates Selumetinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selumetinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Selumetinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Selumetinib supplier is an individual or a company that provides Selumetinib active pharmaceutical ingredient (API) or Selumetinib finished formulations upon request. The Selumetinib suppliers may include Selumetinib API manufacturers, exporters, distributors and traders.
click here to find a list of Selumetinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Selumetinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Selumetinib active pharmaceutical ingredient (API) in detail. Different forms of Selumetinib DMFs exist exist since differing nations have different regulations, such as Selumetinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Selumetinib DMF submitted to regulatory agencies in the US is known as a USDMF. Selumetinib USDMF includes data on Selumetinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Selumetinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Selumetinib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Selumetinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Selumetinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Selumetinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Selumetinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Selumetinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Selumetinib suppliers with NDC on PharmaCompass.
Selumetinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Selumetinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Selumetinib GMP manufacturer or Selumetinib GMP API supplier for your needs.
A Selumetinib CoA (Certificate of Analysis) is a formal document that attests to Selumetinib's compliance with Selumetinib specifications and serves as a tool for batch-level quality control.
Selumetinib CoA mostly includes findings from lab analyses of a specific batch. For each Selumetinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Selumetinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Selumetinib EP), Selumetinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selumetinib USP).